cartessa aesthetics: Devices, Prices, and Buying Guide

Cartessa Aesthetics Company Overview

Cartessa Aesthetics licenses and distributes aesthetic devices from international manufacturers to US practices. Its portfolio centers on platforms that can fit neatly into a med spa menu, especially body contouring and RF microneedling. PHYSIQ comes from Deka, while Vivace has become a familiar name for practices adding energy-based skin treatments.

Cartessa Aesthetics was founded in 2018 and covers 2 device categories tracked by Device Pulse Device Pulse Cartessa profile.

The company is headquartered in New York and operates as a private business. That structure is common in the device-distribution world, but it changes the kind of financial diligence a buyer can perform. Public manufacturers publish filings, earnings calls, and formal guidance. A private distributor gives buyers fewer hard financial markers.

Cartessa’s continuous operation since its founding is the available signal. It has built a recognizable commercial presence around a focused set of platforms and a sales organization that is active in the med spa market. Buyers should still treat financial stability as a practical operating question, not a brand-perception exercise.

Ask who owns the service obligation. Ask where replacement parts come from. Ask whether software access depends on an active agreement. Ask what happens if the manufacturer changes distribution relationships. Those answers tell you more about durability than a polished pitch deck.

Cartessa’s advantage is portfolio breadth within the categories it covers. A practice that buys more than one platform can often consolidate training, service discussions, and account management. The downside is concentration. If a representative frames every clinical need as a reason to add another Cartessa platform, step back and compare the alternatives.

A device should earn its place through patient demand, clinical fit, staffing capacity, and margin. A bundle can be useful. A bundle can also become a closet full of expensive equipment with no durable treatment plan behind it.

Cartessa Devices and Prices

The two Cartessa platforms most buyers encounter are Vivace and PHYSIQ. They serve different treatment categories and carry sharply different capital commitments.

Vivace is an RF microneedling device used for skin-quality treatments. It competes in a crowded category, which gives buyers options and gives patients familiar reference points. Its economics depend on local demand, provider confidence, treatment protocols, consumable costs, and how the practice positions the procedure against nearby competitors.

PHYSIQ is a body-contouring platform using STEP Technology. It sits in a higher-ticket equipment category and requires a more deliberate launch plan. Body contouring can produce strong revenue per treatment, but it also needs consistent consultation volume and disciplined patient selection. Practices that buy it because a competitor has one are usually making the wrong argument to themselves.

New Vivace units sell for $35,000-$55,000 and used units for $15,000-$28,000 on the secondary market Device Pulse Vivace review.

Vivace per-session treatment pricing runs $700-$1,500 Device Pulse Vivace review.

New PHYSIQ units sell for $80,000-$120,000 and used units for $40,000-$70,000 on the secondary market Device Pulse PHYSIQ review.

PHYSIQ per-session pricing runs $500-$1,000 with annual maintenance averaging $3,000-$6,000 Device Pulse PHYSIQ review.

The table is a starting point, not a purchase recommendation. A used platform can lower upfront capital, yet it may come with less predictable service access, uncertain remaining warranty coverage, or a different training path. New equipment can provide cleaner support terms, but only if those terms are written down with explicit pricing.

Review the Vivace review before treating a quoted machine price as the complete cost. For body contouring, the PHYSIQ review is useful for separating the capital decision from the treatment model your practice intends to run.

What the Vivace Costs from Cartessa

A new Vivace generally costs $35,000-$55,000, while used units sell for $15,000-$28,000 on the secondary market. Patients typically pay $700-$1,500 per session, which makes utilization and treatment packaging central to the purchase case.

That range creates room for meaningful differences between proposals. A lower machine price may exclude training, handpieces, consumables, marketing support, warranty coverage, or service. A higher price can be sensible when those elements fit the way your practice operates. It becomes a bad deal when the extras are vague, unused, or impossible to compare.

Get every included item on the proposal. The written document should identify installation, clinical training, provider training, warranty length, service response expectations, consumable requirements, financing assumptions, and any minimum-purchase language. If a rep says an item is standard, it belongs in the paperwork.

Ask for the full treatment workflow as well. RF microneedling devices are sold on outcomes, but your staff needs a repeatable patient journey: consultation, contraindications, consent, treatment time, post-care instructions, photography, follow-up, and rebooking. The best machine in the category will still collect dust if the practice never builds that system.

The Vivace cost breakdown can help frame the capital expense against the operating assumptions a practice needs to validate. If you are choosing between RF microneedling platforms, the Morpheus8 vs Vivace comparison gives the category a more useful frame than a sales call alone.

Negotiating with Cartessa's Sales Team

Cartessa has a reputation for an assertive sales approach. That does not make a proposal bad. It means the buyer should set the pace and define the decision process before urgency takes over the conversation.

Most deals close at 10-20% below list for single-device purchases and 20-30% below list for multi-device bundles Device Pulse Cartessa profile.

Use those ranges as a market reference, then negotiate the entire package. A discount can be valuable, but it is only one part of the contract. Training, warranty extensions, service coverage, consumables, launch support, financing terms, and trade-in treatment can carry more value than a marginal change in the machine price.

Keep the conversation anchored to the platform you would buy without a bundle. If PHYSIQ is the priority, price PHYSIQ cleanly. If Vivace is the priority, do the same. Then ask what a bundle changes, line by line. A bundled quote should improve the economics or reduce an operating burden. It should not make comparison harder.

Trade-in offers deserve particular scrutiny. Ask how the trade-in value was calculated, when it expires, whether it depends on financing approval, and whether the distributor takes title before all promised credits are applied. A verbal assurance about trade-in value is a sales conversation. A signed calculation is a commercial term.

You can also negotiate timing. Training scheduled too early can leave staff forgetting the workflow before the device is in active use. Training scheduled too late can delay revenue after installation. The right timing aligns with the marketing launch, clinical readiness, and the patients already in your pipeline.

The aggressive-sales caveat is simple: urgency belongs to the seller until the buyer has independently verified the economics. A quarter-end deadline may create a useful discount. It does not change your treatment demand, staffing capacity, or tolerance for service downtime.

Stability Questions for a Private Distributor

Private ownership does not make Cartessa unstable. It limits what an outside buyer can verify through public filings. Revenue is not publicly disclosed, and buyers should resist filling that gap with either optimism or suspicion.

The practical diligence is operational. Start with warranty coverage and service responsibility. Find out whether Cartessa services the equipment directly, relies on the original manufacturer, or uses a third party. Ask how parts are stocked, how software updates are handled, and who has authority to resolve a device issue when patient appointments are already booked.

Request references from practices similar to yours. A high-volume cosmetic dermatology office may have a different support experience from a smaller med spa. Ask about installation, training quality, service responsiveness, replacement parts, and whether the promised commercial support appeared after the sale.

Software deserves its own conversation. Confirm whether updates, licenses, patient-management tools, or treatment protocols require recurring fees. Ask what capabilities remain available if you sell the device later. Secondary-market value depends partly on whether the next owner can access the software, service, and training needed to operate it confidently.

Then ask a harder portfolio question: is the platform strategic for Cartessa? Distributors shift their attention as manufacturer relationships evolve and new devices arrive. A flagship platform usually receives more sales attention, clinical education, and service coordination. A legacy platform can become harder to support even when it remains technically capable.

Cartessa wins when its sales and support model gives a practice a clean path from equipment purchase to an active treatment line. The buyer loses when a package looks complete at signing and turns fragmented once the machine is installed. Which parts of the proposal will still matter after the first patient is treated?